MY205197A - Methyllactam ring compound and pharmaceutical use thereof - Google Patents

Methyllactam ring compound and pharmaceutical use thereof

Info

Publication number
MY205197A
MY205197A MYPI2020003891A MYPI2020003891A MY205197A MY 205197 A MY205197 A MY 205197A MY PI2020003891 A MYPI2020003891 A MY PI2020003891A MY PI2020003891 A MYPI2020003891 A MY PI2020003891A MY 205197 A MY205197 A MY 205197A
Authority
MY
Malaysia
Prior art keywords
methyllactam
pharmaceutical use
ring compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MYPI2020003891A
Other languages
English (en)
Inventor
Tomoya Miura
Yoshinori Tamatani
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MY205197A publication Critical patent/MY205197A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI2020003891A 2018-03-01 2019-02-28 Methyllactam ring compound and pharmaceutical use thereof MY205197A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01
PCT/JP2019/007799 WO2019168096A1 (ja) 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
MY205197A true MY205197A (en) 2024-10-07

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020003891A MY205197A (en) 2018-03-01 2019-02-28 Methyllactam ring compound and pharmaceutical use thereof

Country Status (21)

Country Link
US (4) US11014910B2 (cg-RX-API-DMAC7.html)
EP (1) EP3760624A4 (cg-RX-API-DMAC7.html)
JP (3) JP7206132B2 (cg-RX-API-DMAC7.html)
KR (1) KR102795351B1 (cg-RX-API-DMAC7.html)
CN (1) CN111757877B (cg-RX-API-DMAC7.html)
AR (1) AR114418A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019227770B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016788A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087859A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002199A1 (cg-RX-API-DMAC7.html)
IL (1) IL276311B2 (cg-RX-API-DMAC7.html)
MA (1) MA52427A (cg-RX-API-DMAC7.html)
MX (1) MX2020009070A (cg-RX-API-DMAC7.html)
MY (1) MY205197A (cg-RX-API-DMAC7.html)
PE (1) PE20210123A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551340A1 (cg-RX-API-DMAC7.html)
SA (1) SA520420037B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007120UA (cg-RX-API-DMAC7.html)
TW (1) TWI805699B (cg-RX-API-DMAC7.html)
WO (1) WO2019168096A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202004600B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途
CN114585387B (zh) * 2019-09-04 2024-10-29 日本烟草产业株式会社 利用联用药物的糖尿病的治疗或预防方法
CN114641314B (zh) * 2019-09-04 2024-05-28 日本烟草产业株式会社 慢性肾脏病的治疗或预防方法
EP4122495A4 (en) * 2020-03-19 2024-03-27 Japan Tobacco Inc. Treatment or prevention method for chronic heart failure

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
RU2332412C2 (ru) 2003-02-07 2008-08-27 Дайити Фармасьютикал Ко., Лтд. Производные пиразола
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
DE602005017895D1 (de) 2004-07-07 2010-01-07 Merck & Co Inc Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
CN101243074A (zh) * 2005-06-08 2008-08-13 日本烟草产业株式会社 杂环化合物
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
EP1991528A2 (en) 2006-01-18 2008-11-19 Siena Biotech S.p.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CA2650566A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2064222B1 (en) * 2007-04-02 2014-05-07 Theracos, Inc. Benzylic glycoside derivatives and methods of use
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018016671A2 (pt) * 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
TWI805727B (zh) 2018-04-04 2023-06-21 日商日本煙草產業股份有限公司 經雜芳基取代之吡唑化合物及其醫藥用途

Also Published As

Publication number Publication date
MX2020009070A (es) 2020-10-08
SA520420037B1 (ar) 2024-07-28
US20220064148A1 (en) 2022-03-03
CA3087859A1 (en) 2019-09-06
US20240174646A1 (en) 2024-05-30
TW202000660A (zh) 2020-01-01
CN111757877A (zh) 2020-10-09
MA52427A (fr) 2021-01-06
IL276311A (en) 2020-09-30
BR112020016788A2 (pt) 2021-01-12
JP2025026615A (ja) 2025-02-21
RU2020131756A (ru) 2022-03-28
CN111757877B (zh) 2023-10-27
CL2020002199A1 (es) 2020-12-18
AU2019227770A1 (en) 2020-07-09
KR102795351B1 (ko) 2025-04-16
AR114418A1 (es) 2020-09-02
JP2023026566A (ja) 2023-02-24
PH12020551340A1 (en) 2021-05-31
WO2019168096A1 (ja) 2019-09-06
US20190352284A1 (en) 2019-11-21
SG11202007120UA (en) 2020-08-28
AU2019227770B2 (en) 2023-10-05
ZA202004600B (en) 2022-03-30
US20260152490A1 (en) 2026-06-04
JP2019151627A (ja) 2019-09-12
IL276311B2 (en) 2023-10-01
IL276311B1 (en) 2023-06-01
EP3760624A4 (en) 2021-11-03
EP3760624A1 (en) 2021-01-06
US11014910B2 (en) 2021-05-25
PE20210123A1 (es) 2021-01-19
KR20200128033A (ko) 2020-11-11
TWI805699B (zh) 2023-06-21
JP7206132B2 (ja) 2023-01-17

Similar Documents

Publication Publication Date Title
PH12019501685A1 (en) Quinazone compound
ZA202206923B (en) New methylquinazolinone derivatives
PH12016502103B1 (en) Novel disubstituted 1,2, 4-triazine compound
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
PH12020551340A1 (en) Methyllactam ring compound and pharmaceutical use thereof
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
MX2021007247A (es) Derivados de rapamicina.
CR20200151A (es) Compuestos bicíclicos y métodos de utilización de los mismos
PH12016502246A1 (en) Carboxamide derivatives
MX2018014813A (es) Composiciones antibacterianas.
MY194711A (en) Novel annelated phenoxyacetamides
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2016014946A (es) Derivados de carboxamida.
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
MX379373B (es) Derivado de sulfonamida heterocíclico y medicina que contiene el mismo.
MY194941A (en) C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
JOP20230099A1 (ar) تركيبات صيدلية
BR112017025356A2 (pt) composto, composição farmacêutica, e, fármaco.
EA201891136A1 (ru) Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль
TR201722852A2 (tr) Mesalazi̇ni̇n oral farmasöti̇k kompozi̇syonlari
MX2018007272A (es) Composicion farmaceutica de liberacion pulsatil que comprende naftazona o una de sus sales.
PH12016502247A1 (en) Carboxamide derivatives